Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

50%

Ph phase_3

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

3(50.0%)

Phase 3Large-scale testing

3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(1)

Detailed Status

Completed5

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 13 (50.0%)

Phase 33 (50.0%)

Trials by Status

completed583%

withdrawn117%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_3

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

NCT02787239

completedphase_1

A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs

NCT03355872

completedphase_3

Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis

NCT03522415

completedphase_1

A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

NCT02584920

completedphase_1

A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas

NCT03218072

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT02787239Phase 3

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

Completed

NCT03355872Phase 1

A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs

Completed

NCT03522415Phase 3

Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis

Completed

NCT02584920Phase 1

A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

Completed

NCT03218072Phase 1

A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas

Completed

NCT04671420Phase 3

Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.